Background: The endocannabinoid system functions through two well characterized receptor systems, the CB 1 and CB 2 receptors. Work by a number of groups in recent years has provided evidence that the system is more complicated and additional receptor types should exist to explain ligand activity in a number of physiological processes. Experimental approach: Cells transfected with the human cDNA for GPR55 were tested for their ability to bind and to mediate GTPgS binding by cannabinoid ligands. Using an antibody and peptide blocking approach, the nature of the Gprotein coupling was determined and further demonstrated by measuring activity of downstream signalling pathways.
Introduction
Preparations of Cannabis sativa have been used for medicinal and recreational purposes for at least 4000 years and extracts of C. sativa contain over 60 different pharmacologically active components the most prominent being D
9
-tetrahydrocannabinol (D 9 -THC) and cannabidiol (Mechoulam, 1970a; Mechoulam et al., 1970b; Howlett, 2002) . Cannabinoids exert their effects by binding to specific receptors located in the membrane of the cell. Two types of highaffinity cannabinoid receptors have been identified so far by molecular cloning; CB 1 receptors (Devane et al., 1988; Matsuda et al., 1990) , and CB 2 receptors (Munro et al., 1993) . Both CB 1 and CB 2 are coupled to the G i , G-protein signal transduction pathway. Activation of these cannabinoid receptors leads to inhibition of adenylate cyclase and activation of mitogen-activated protein (MAP) kinase. CB 1 receptors can also modulate ion channels, inhibiting N-, and P/R-type calcium channels, stimulating inwardly rectifying potassium channels and enhancing the activation of A-type potassium channels (for recent reviews of cannabinoid signal transduction see Howlett, 2004; Demuth and Molleman, 2006) .
Cannabinoid type 1 (CB 1 ) receptors are primarily, but not exclusively expressed in the CNS and are believed to mediate the CNS effects of endogenous (for example, anandamide) and exogenously administered cannabinoids. Peripherally, CB 1 receptor expression is found in the pituitary gland, immune cells, reproductive tissues, gastrointestinal tissues, superior cervical ganglion, heart, blood vessels, lung, bladder and adrenal gland (reviewed by Howlett, 2002) . Recently, the liver and adipose has been added to the list (Cota et al., 2003; Osei-Hyiaman et al., 2005) . CB 1 receptors are also located on central and peripheral nerve terminals and when activated, seem to suppress the neuronal release of excitatory and inhibitory transmitters for example, acetylcholine, noradrenaline, dopamine, 5-hydroxytryptamine, g-amino butyric acid, glutamate and aspartate (Pertwee, 1997 (Pertwee, , 2001 Ong and Mackie, 1999) adding to the complexity of the physiological responses to the endocannabinoids.
CB 2 receptor expression is restricted to the periphery, mainly in immune cells with particularly high levels in B cells and natural killer cells (Galiegue et al., 1995) although it has been reported that the CB 2 receptor is expressed in microglia cells of the CNS and in brain stem neuronal cells (Van Sickle et al., 2005) .
Some studies suggest that endocannabinoids regulate multiple physiological and pathological reproductive functions (Maccarrone et al., 2002) and that endocannabinoids such as 2-arachidonoylglycerol play a role in the progression of the pathophysiology of shock (Cainazzo et al., 2002) and act as immunomodulators (Parolaro et al., 2002) . Others have shown that CB 2 receptors play a very important role in the stimulation of growth in most haematopoietic lineages (Valk et al., 1997; Derocq et al., 2000) . Thus, cannabinoid receptors and endocannabinoids are physiologically or pathophysiologically relevant in a great diversity of tissues and organs like the CNS and cardiovascular, reproductive, endocrine, immune and gastrointestinal systems. Particularly, the CNS and its hypothalamic appetite-regulating control system have attracted much attention over the last ten years and endocannabinoids have classically been shown to play a role in the physiological regulation of food intake (Sofia and Knobloch, 1976; Anderson-Baker et al., 1979; Pacheco et al., 1993; Berry and Mechoulam, 2002; Fride, 2002) , effects that are inhibited by the non-endogenous
A number of endogenous ligands such as anandamide, 2-arachidonoylglycerol, noladin ether, palmitoylethanolamine, virodhamine and oleoylethanolamide (OEA) have been identified, which are believed to modulate the cannabinoid system via the previously identified CB 1 and CB 2 receptors, or by their action at as-yet unidentified receptors.
In recent years, a number of studies have suggested the existence of additional cannabinoid receptors that function in these processes and these reports have been reviewed by Begg et al. (2005) . In this study we show that the orphan Gprotein-coupled receptor, GPR55, is a novel cannabinoid receptor with an ability to interact with and be modulated by endogenous, plant and synthetic cannabinoid ligands and to be a candidate for one of the non-CB 1 /CB 2 receptors, described by others.
Methods
Cloning of hGPR55 hGPR55 (EMBL accession no. BC032694) was amplified from human genomic DNA by polymerase chain reaction (PCR) and sub-cloned into mammalian expression plasmids pIRESneo2 and pcDNA3 using standard techniques.
Expression profiling GPR55 mRNA levels in human and mouse tissues were analysed by quantitative real-time PCR analysis using ABI PRISM 7900 HT sequence detection system (Applied Biosystems, Hercules, CA, USA). Primer/probe sets for hGPR55 were: 5 0 -TCTACATGATCAACCTGGCAGTCT-3 0 , 5 0 -CTGGGA CAGGACCATCTTGAA-3 0 and 5 0 -FAM-TGACCTGCTGCTGG TGCTCTCCC-TAMRA-3 0 , and for mGPR55 were: 5 0 -CTATCTA CATGATCAACTTGGCTGTTT-3 0 , 5 0 -TGTGGCAGGACCATCT TGAA-3 0 and 5 0 -FAM-CGATTTACTGCTGGTGCTCTCCCTCC C-TAMRA-3 0 . To determine relative mRNA levels of GPR55, results were normalized to its content of the mRNA encoding the ribosomal protein 36B4 (used as an internal standard).
Cell transfection and membrane preparation
Human embryonic kidney-HEK293s cells (5 Â 10 6 ) were seeded in T75 flasks and after 24 h, cells were transiently transfected with 10 mg of relevant plasmid using Lipofectamine Plus (Invitrogen, Carlsbad, CA, USA). Membranes were prepared after 48 h using standard methods and stored at À80 1C. Protein concentration was measured according to the method of Bradford (Bio-rad Laboratories, Foster City, CA, USA) (Bradford, 1976) . CB 1 and CB 2 membranes were commercially available (PerkinElmer).
Radioligand binding assays
Radioligand binding was initiated by the addition of 5 mg of membrane protein to each well of a 96-well plate containing 50 nM [ Non-specific binding was determined in the presence of 20 mM unlabelled GTPgS (Sigma). The reaction was terminated by addition of ice-cold wash buffer (50 mM Tris-HCl, 5 mM MgCl 2 , 50 mM NaCl, pH 7.4) followed by rapid filtration under vacuum through Wallac GF/B glassfibre filters using a cell harvester (Skatron). The filters were left to dry for 30 min at 50 1C, then a paraffin scintillant pad was melted onto the filters and the bound radioactivity was determined using a microbeta scintillation counter (Wallac). Antagonist potency was determined versus an EC 80 concentration of CP55940 that was determined empirically on the day of the experiment. Data were fitted using the equation
) and the EC 50 estimated where A is the non-specific binding, B is the total binding, C is the IC 50 and D is the slope.
Peptide and antibody blocking of [

S]-GTPgS binding assays [
35 S]-GTPgS binding assays were performed as above with additional pre-incubation of membranes with and without peptides or antibodies for the G-protein subunits Ga 13 , Ga i and Ga s for 15 min at 30 1C (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Data were analysed using paired t-test (**Po0.05; ***Po0.01).
Pertussis toxin treatment
Cell transfections were conducted as described above with the exception that the cells prior to harvesting were preincubated with Pertussis toxin (Sigma) overnight (0.1 mg ml À1 final concentration). The cells were then harvested and membranes were prepared as described above.
Plate-based FLIPR Ca 2 þ assays
In brief, 1 day before the assay was performed, HEK293 cells expressing GRP55 were plated in 96-well, black-walled, assay plates, at a density of 25 000 cells per well. These plates were then returned to the cell-culture incubator until 1.5 h before the assay when they were removed and the cells were loaded with the Ca 2 þ reporter dye Fluo4 (Invitrogen) for 1 h in a cell-culture incubator. After this, the plates were placed into a fluorescent imaging plate reader (FLIPR) to monitor fluorescence (l ex ¼ 488 and l EM ¼ 540 nm) before and after the addition of ligands of interest.
Determination of rhoA, rac1 and cdc42 activity RhoA, rac1 and cdc42 activity was measured according to the manufacturer's instructions (Upstate Biotechnology Inc., Charlottesville, Virginia, USA). HEK293s GPR55-transfected cells were seeded on six-well plates, grown to 80% confluence, and serum-starved for 24 h. Following treatment with selected compounds at 37 1C for 15 min, the cells were washed with phosphate-buffered saline and harvested with 500 ml of lysis buffer provided by the manufacturer, with the addition of a mixture of protease inhibitors (Roche Molecular Biochemicals, Basel, Switzerland). The cell lysates were clarified by centrifugation at 15 000 g for 1 min. For a negative control, cell lysate was incubated with 1 mM GDP for 15 min at 30 1C. The cell lysates were then incubated with 10 mg of GST-RBD-agarose (Rho-binding domain of rhotekin) or GST-PBD-agarose (p21-binding domain of human PAK-1) to precipitate GTP-bound rhoA and GTP-bound rac1 and cdc42, respectively. The beads were then washed three times with lysis buffer and samples were prepared for electrophoresis by adding 1 Â sodium dodecyl sulphate loading dye. Samples were boiled for 5 min and resolved by 12% sodium dodecyl sulphate-polyacrylamide gel electrophoresis . Bound rhoA, rac1 and cdc42 were detected by western blot using the appropriate polyclonal antibodies specific for rac1, cdc42
(1:1000; Upstate Biotechnology) and rhoA (1:200; Santa Cruz Biotechnology).
Results
Cloning and sequence determination of GPR55 Nucleotide primers designed against the 5 0 -and 3 0 -ends of human, mouse and rat gpr55 were used to isolate open reading frames for GPR55 from the three species using genomic DNA. The sequence of the human gene was similar but not identical to that already described (Sawzdargo et al., 1999) , however it was consistent with the human genome sequence. The sequence of all clones isolated differed in that there was a nucleotide insertion and deletion at positions 393 and 427 respectively, resulting in a frame shift of the translated sequence, consequently changing 11 amino acids at the predicted junction of intracellular loop 2 and transmembrane helix 4 (Figure 1 ). Since we could find no evidence for the existence of the previously published sequence, we concluded that the difference originated from a sequencing error by the authors (Sawzdargo et al., 1999) .
The rat and mouse genes were cloned using a similar approach and their sequences were found to be identical to those found in GenBank (AC119315 (position 129078-130085) AC107707 (position 31198-32181)) demonstrating 75 and 78% identity to the human sequence respectively (Figure 1 ). Both the rat and mouse sequences are consistent with the human genome sequence in the region of the intracellular loop 2-transmembrane helix 4 region rather than the published sequence (Sawzdargo et al., 1999) containing the insertion and deletion (Figure 1 ). Despite GPR55, a novel cannabinoid receptor E Ryberg et al the low level of identity between the human and rodent forms of GPR55, the genomic linkage confirms that the rodent genes are orthologues of the human gpr55. Phylogenetically, the GPR55 sequence belongs to a cluster of receptors that are either orphans (GPR35, GPR92, P2Y5) or have been recently deorphanized (P2Y9 (Noguchi et al., 2003) , GPR40 (Briscoe et al., 2003) , GPR41 and GPR43 (Brown et al., 2003) ).
Expression profile of GPR55
We next investigated the expression pattern of GPR55 in a panel of mouse tissues using quantitative PCR (Figure 2 ). GPR55 mRNA is found in a number of tissues with the highest mRNA levels detected in the adrenals, parts of the gastrointestinal tract, as well as in the CNS. As seen with CB 1 receptors, a broad distribution of GPR55 mRNA is found in brain tissue, however the levels are significantly lower than those for CB 1 (Figure 2 , inset).
GPR55 binds and is activated by cannabinoid ligands
To test the possibility that GPR55 maybe a cannabinoid receptor, we generated an N terminus FLAG-tagged human GPR55 and transiently transfected the plasmid containing the cDNA into HEK293s cells. Cell-surface expression of the recombinant receptor was confirmed using an anti-FLAG antibody ( Figure 3 ). We then examined the ability of the cannabinoid receptor radioligands [ However, in membranes prepared from HEK293s cells transfected with the FLAG-tagged cDNA for human GPR55, a clear specific binding for [
VHQDSMVSRA Figure 1 Alignment between human (hGPR55), mouse (mGPR55) and rat (rGPR55) GPR55 protein sequences. The putative positions of the transmembrane regions (TM1-7), extracellular loops (EC1-3) and intracellular loops (EC1-3) are shown. The amino-acid differences in the previously published sequence (Sawzdargo et al., 1999) for human GPR55 at the IC2/TM4 boundary are shown above the sequences.
Figure 2 mRNA expression levels of GPR55 and CB 1 receptors in mouse tissues measured by quantitative PCR relative to m36B4. Tissues were dissected from C57BL/6 female mice. Samples from different mice were processed individually in all subsequent steps; RNA preparation, cDNA synthesis and quantitative PCR. Data are mean values7s.e.m. using tissues from eight (GPR55) or four mice (CB 1 ) and presented as per cent of the ubiquitously and homogenously expressed ribosomal protein 36B4.
GPR55, a novel cannabinoid receptor E Ryberg et al expression was confirmed using an anti-FLAG antibody and this cell line was used for further studies. We, next determined whether the interaction of CP55940 with GPR55 had a functional consequence. Since GTPgS has the potential to pick up activation of most heterotrimeric G proteins if the experimental conditions are appropriate, we tested membranes expressing GPR55 using a factorial design strategy with and without 1 mM CP55940 varying GDP, MgCl 2 , NaCl and saponin. A number of the conditions tested generated an increased GTPgS binding in the GPR55-containing membranes, but not with control membranes, in the presence of CP55940 (data not shown). Using the optimum condition identified (see Methods), we found that CP55940 stimulated GTPgS binding with an EC 50 of 5 nM ( Figure 5a and Table 1 ). With this finding we went on to evaluate other cannabinoid ligands for their ability to promote GTPgS binding via GPR55.
A number of endogenous cannabinoid ligands have been identified and characterized to date and we therefore examined their effect upon GPR55. The endocannabinoid anandamide stimulated GTPgS binding with an EC 50 of 18 nM ( Figure 5b and Table 1 ). The other endocannabinoids, 2 arachidonoylglycerol (2-AG), noladin ether, palmitoylethanolamide, virodhamine and OEA all stimulated GTPgS binding with EC 50 values of 3, 10, 4, 12 and 440 nM respectively GPR55, a novel cannabinoid receptor E Ryberg et al (Table 1) . In parallel experiments, all these compounds generated the expected activities at CB 1 and CB 2 receptors (Table 1) . None of these ligands had any effect when tested under identical conditions against membranes prepared from untransfected cells. Of note is the efficacy of virodhamine which under the assay conditions used is approximately 160% that of the other endocannabinoid ligands, noladin ether and 2-AG and double the efficacy of anandamide. 
GPR55, a novel cannabinoid receptor E Ryberg et al
We next tested D
9
-THC, the psychoactive component of the cannabis plant C. sativa, for its activity at GPR55. D 9 -THC activated GTPgS binding with an EC 50 of 8 nM (Figure 5a and Table 1 ). We also examined the effect of cannabinol, cannabidiol and related compounds. Cannabidiol was without effect as an agonist in the GTPgS assay. However, cannabidiol was able to antagonize the agonist effect of CP55940 with an IC 50 of 445 nM ( Figure 5b and Table 2 ). Abnormal cannabidiol functioned as an agonist with an EC 50 of 2.5 mM while a similar compound O1602, was significantly more potent at 13 nM. (À) 11-OH-8-Tetrahydrocannabinoldimethylheptyl (HU210) is a highly potent CB 1 agonist and also demonstrated agonist activity at GPR55 with a potency of 26 nM, which is more than a 100-fold less potent than that found in parallel experiments at the CB 1 receptor (Table 1) . A commonly used tool ligand of the cannabinoid system is WIN55,212-2. Consistent with the demonstrated lack of binding activity of this compound in our initial experiments, we observed no functional activity of WIN55,212-2 as either an agonist or antagonist ( Figure 5c and Table 1 ). Finally, we tested the ability of known antagonists of CB 1 receptors for their effect at GPR55. 1-(2,4-Dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-4-morpholinyl-1H-pyrazole-3-carboxamide (AM281) was without effect as either an agonist or antagonist whereas 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-1-piperidinyl-1H-pyrazole-3-carboxamide (AM251) behaved as an agonist with an EC 50 of 39 nM. In all the experiments described above, the data were the same whether the receptor was expressed with or without the FLAG epitope.
G-protein coupling of GPR55
We next investigated the nature of the signalling pathway activated by GPR55 by examining the G-protein coupling. In the first instance, we examined the effect of Pertussis toxin on the ability of GPR55 to mediate GTPgS binding. Membranes prepared from cells treated with toxin were still able to mediate a robust response to compounds shown to be agonists of GPR55 (data not shown), suggesting that G i Gproteins are not involved downstream of GPR55. We also tested GPR55-expressing HEK293s cells using FLIPR to determine whether there was evidence of a calcium signal that could be indicative of G q coupling. No agonist-mediated calcium signalling was detected when compared to untransfected cells suggesting that G q was not coupling to GPR55. To further investigate the G-protein signalling pathway downstream of GPR55 we took an antibody and peptide blocking approach in the GTPgS assay. Peptides equivalent to the last 12 amino acids of Ga i1/2 , Ga i3 , Ga s and Ga 13 were incubated with GPR55-containing membranes for 15 min prior to performing GTPgS assays. The peptides equivalent to G i1/2 , G i3 and G s had no effect upon the GTPgS signal consistent with the lack of effect of Pertussis toxin (Figure 6a) . However, the G 13 peptide dose dependently inhibited GTPgS binding suggesting that this peptide makes a specific interaction with GPR55 and prevents the receptor coupling to and activating G 13 (Figure 6a ). A similar experiment was then performed using antibodies raised against the C-terminal peptides of the different G proteins. Consistent with the peptide studies anti-G i1/2 , anti-G i3 and anti-Ga s had no effect upon GTPgS binding mediated by GPR55 (Figure 6b ). At the same time, anti-Ga 13 prevented GTPgS binding in a dose-dependent manner, demonstrating Figure 6 Mapping G-protein coupling of GPR55. (a) Basal and 1 mM O1602 stimulated GTPgS binding (% activity, mean7s.e.m.) in human GPR55-expressing membranes in the absence and presence of various concentrations of peptides equivalent to the C termini of Ga 13 , Ga i1/2 , Ga i3 and Ga s . (b) Basal and 1 mM stimulated GTPgS binding (% activity, mean7s.e.m.) in human GPR55-expressing membranes in the absence and presence of various dilutions of antibodies that bind to the C termini of Ga 13 , Ga i1/2 , Ga i3 and Ga s . Data were analysed using paired t-test (**Po0.05; ***Po0.01; n ¼ 5). GPR55, a novel cannabinoid receptor E Ryberg et al that the GTPgS signal being measured as a consequence of agonist activity at GPR55 was a result of G 13 activation (Figure 6b ). To further demonstrate that the signalling of GPR55 was Ga 13 -mediated, we performed additional studies. Cells stably expressing human GPR55 were transiently transfected with plasmid DNA containing the human Ga 13 gene or with vector control. As shown in Figure 7 , while the vector control did not change GTPgS readout, the membranes prepared from the Ga 13 -transfected cells showed an augmented signal in response to cannabinoid ligands, indicative of increased expression of the coupling G protein.
Downstream signalling by GPR55
Assuming therefore that GPR55 is Ga 13 -coupled, it is reasonable to expect that downstream signalling pathways of the G protein will be activated in a GPR55-dependent manner. To this effect, we looked at the activation of rhoA, cdc42 and rac1 in response to various ligands in GPR55-expressing and control HEK293s cells. Figure 8 shows that both anandamide and O1602 but not WIN55,212-2 treatment induced the activation of rhoA, cdc42 and rac1. This effect was blocked by the GPR55 antagonist, cannabidiol.
Discussion and conclusions
In recent years, it has been suggested that there are cannabinoid receptors in addition to CB 1 and CB 2 in brain (Di Marzo et al., 2000; Hajos et al., 2001; Monory et al., 2002) , vascular endothelium (Jarai et al., 1999) and vascular smooth muscle (Ho and Hiley, 2003) as well as in the immune system (Kaplan et al., 2003) . In this study, we describe that the orphan G-protein-coupled receptor, GPR55, is expressed in these tissues and is liganded by a range of endogenous, plant-derived and synthetic cannabinoid ligands.
GPR55 was specifically bound and activated by the synthetic cannabinoid ligand CP55940 (Table 1) . CP55940 interacts with GPR55 at a potency 25-fold lower than at CB 1 in the comparable experimental system used here. [ 3 H]-CP55940 has been used in several studies (Zimmer et al., 1999; Buckley et al., 2000) to examine cannabinoid receptor distribution. Because GPR55 binds the radioligand [ 3 H]-CP55940 it may be expected that this radioligand would detect the presence of GPR55, especially in CB 1 and CB 2 knockout mice, but this has not been the case (Zimmer et al., 1999) . We conclude that the lower affinity of CP55940 for GPR55 without suitably adapted conditions may prevent the detection of GPR55. Taken together, these findings imply that the detection of GPR55 using [ H]-CP55940 in some of the studies reported, a specific binding to GPR55 would not be detectable. WIN55,212-2 has however been reported to influence activity at a novel cannabinoid receptor in the CNS (Hajos et al., 2001) and, as WIN55,212-2 does not bind to or induce activity of GPR55, this receptor is not the brain receptor described, pointing to the presence of at least two novel non-CB 1 /CB 2 receptors in the CNS, one of which is GPR55.
Another area of non-CB 1 /CB 2 pharmacology relevant for GPR55 is control of vascular tone. We have shown that WIN55,212-2 is not a ligand for GPR55 while abnormal cannabidiol is an agonist and cannabidiol is an antagonist. WIN55,212-2 has been shown to be without effect at novel CB receptors in the vasculature while abnormal cannabidiol behaves as an agonist and cannabidiol is an antagonist (Jarai et al., 1999) . The finding that cannabidiol is an antagonist of GPR55 is interesting since until recently (Thomas et al., 2007) it has not been shown to have any significant effect on CB 1 and CB 2 receptor signalling (Pertwee, 1997) , as confirmed by our studies (Table 1) . Clearly, the precise pharmacology of this ligand remains to be determined. In addition, O1602, an analogue of abnormal cannabidiol Figure 8 Activation of GPR55 leads to activation of rhoA, cdc42 and rac1. Cells transfected with GPR55 demonstrated O1602-(1 mM) and anandamide (1 mM)-mediated activation of the small G proteins rhoA, cdc42 and rac1 while the non-GPR55-activating ligand WIN55,212-2 had no effect. The activation was blocked by cannabidiol (10 mM) while the positive control GTPgS and negative controls (GDP and dimethyl sulphoxide ) generated the expected responses. The blots shown are representative of three independent experiments.
Figure 7
Transfection of Ga 13 into GPR55-expressing HEK293 cells leads to an increased GTPgS signal via GPR55. Membranes prepared from HEK293s cells and HEK293s-GPR55-expressing cells were transfected with transfected with either control or Ga 13 -containing plasmids and tested in a GTPgS with and without 1 mM O1602. Membranes containing GPR55 demonstrate a clear increase in GTPgS binding as a result of overexpression of Ga 13 . Data (mean7s.e.m.) were analysed using paired t-test (**Po0.05; n ¼ 5).
GPR55, a novel cannabinoid receptor E Ryberg et al reported to be active in vaso-relaxation (Jarai et al., 1999) was found by us to be a potent agonist of GPR55. Another aspect of the GPR55 pharmacology consistent with a novel cannabinoid receptor in the vasculature is the potent activation by virodhamine (Ho and Hiley, 2004 ) which appears to be more selective for GPR55 versus CB 1 and CB 2 receptors compared with anandamide (Table 1) . Taken together, these findings suggest that GPR55 is a prime candidate for a cannabinoid vascular tone-controlling receptor. Other aspects of the GPR55 receptor may seem inconsistent with a role in vascular tone control. HU210, widely used in the study of cannabinoids, has been shown to affect many physiological processes including vascular tone control and this activity has been attributed to its activity at CB 1 receptors since no effect is observed in CB 1 knockout mice. However, it needs to be considered if appropriate concentrations have been selected to conclusively say that HU210 has no effect through non-CB 1 -mediated processes (Jarai et al., 1999) , since HU210 is more than 100 times less potent at GPR55 than at CB 1 receptors (Table 1) Yet another aspect of non-CB 1 /CB 2 pharmacology that is relevant to GPR55 based on its expression profile, is immune cell function and cell migration. We show that palmitoylethanolamide (PEA) is a potent and selective agonist of GPR55. PEA has been reported to affect inflammatory activities (Lambert et al., 2002) and microglial cell migration and it has been accepted that these effects, at least in part, are via CB 2 receptors. Nevertheless, PEA has also been demonstrated to be activating antiinflammatory activities through peroxisome proliferatoractivated receptor a mediation (Lo Verme et al., 2005) and thus such contributions to an anti-inflammatory effect have to be considered. However, PEA activity in microglial-cell migration also overlaps with an activity of abnormal cannabidiol at the so-called abnormal cannabidiol-sensitive receptors in the same cells , and could be said to advocate GPR55 as a target for its function. (Table 2) .
It is also noteworthy that anandamide, the predominant circulating endocannabinoid, activated GPR55 with a potency equivalent to that activating CB 1 and CB 2 receptors, demonstrating that this ligand has the potential to influence signalling by all three receptors equally. Anandamide has been found to be active at non-CB 1 /CB 2 receptors (Begg et al., 2005) and GPR55 should now be considered a candidate for these receptors. In contrast, PEA, 2-AG and virodhamine show significantly more potent action through GPR55 than through either CB 1 or CB 2 , suggesting that GPR55 is more likely to be the cognate receptor for these ligands.
Most of the reports describing non-CB 1 /CB 2 receptors suggest that several, though not all (for example Vaccani et al. (2005) of these receptors are G i -coupled, since they appear to be Pertussis toxin sensitive (Begg et al., 2005) . In contrast, GPR55 appears to be G 13 coupled at least in the recombinant systems we have tested. This observation may be taken to disqualify GPR55 for a role in the Pertussis toxinsensitive cannabinoid-mediated activities. However, the mechanism of Pertussis toxin action results in preventing G i G proteins interacting with their receptors. Since G i G proteins are highly abundant and the levels of G 13 are considered to be lower, it should be considered that the Pertussis toxin effect may also be a consequence of G 13 being bound and sequestered by G i -coupled receptors resulting in a dominant-negative effect. Furthermore, we have demonstrated that GPR55 also mediates activation of the small G proteins rhoA, cdc42 and rac1. Such an observation is consistent with the G13 coupling we have described and fits well with the cannabidiol-mediated effects on cell migration that are Pertussis toxin insensitive and described for non-CB 1 /CB 2 cannabinoid receptors in glial cells (Vaccani et al., 2005) .
The results presented herein demonstrate that the orphan G-protein-coupled receptor, GPR55, binds a range of endogenous, plant-derived and synthetic cannabinoid ligands. While the data themselves do not, at this stage, point to an unequivocal role for this receptor in any particular cannabinoid function, the comparative ligand profile that we have described provides the tools to start dissecting the functions of GPR55.
